Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2836882 | 0.83 | NPC1 (0.41) | SLC6A4SLC6A2SLC6A3HRH3KMT2A | |
| SCHEMBL3579002 | 0.83 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3HRH3MEN1 | |
| SCHEMBL10954592 | 0.81 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3HRH3MEN1 | |
| SCHEMBL2839830 | 0.79 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3HRH3NPC1 | |
| SCHEMBL2840442 | 0.77 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3575325 | 0.77 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3HRH3MEN1 | |
| SCHEMBL2843946 | 0.76 | NPC1 (0.42) | SLC6A4SLC6A2SLC6A3HRH3NPC1 | |
| SCHEMBL9797340 | 0.74 | HDAC1 (0.41) | SLC6A4SLC6A2SLC6A3HRH3MEN1 | |
| Hydrochloric Acid SCHEMBL2879263 | 0.74 | HTR2A (0.41) | MCHR1 | |
| Fumaric Acid SCHEMBL10956074 | 0.73 | LMNA (0.41) | SLC6A4SLC6A2SLC6A3HRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217031-B2 | Heteroaryl derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100048537-A1 | HETEROARYL DERIVATIVES | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048537-A1 | HETEROARYL DERIVATIVES | OPRD1, OPRM1, OPRK1 | SLC6A4 185/4885SLC6A2 196/4885SLC6A3 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.